KYORIN Pharmaceutical (4569) · RiskFirst stated

Risks Relating to Competition for Talent and Diversity

First written in FY2026. . Latest entry: FY2026.

1entries

1years

0from disclosures

How it moved

Same theme, other companies

Declining competitiveness due to difficulty securing diverse talent and delays in developing an environment in which it can thriveA theme 20 companies write about · 20 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2024: 3 of 11 companies on the "Worse" side.

6 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.

Showing 14 of the 20 companies compared. The sentences above are computed from all 20.

Full recordFilings, disclosures and news, newest first

FY2026First statedAnnual report
「If intensified competition for talent or rapid changes in the working environment prevent us from securing excellent personnel and a diverse workforce, including women, this could materially affect the Group’s results and financial condition through disruption to business activities.」
The Group newly identified the risk that competition for talent and changes in the working environment could prevent it from securing highly skilled and diverse personnel.

Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next

No upcoming earnings preview for KYORIN Pharmaceutical yet.

News

No news is linked to this thread yet. When an article touches it, it will appear here by date.